UCSF Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, San Francisco, Calif.
UCSF Adult Allergy/Immunology Clinic, San Francisco, Calif.
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2672-2679.e2. doi: 10.1016/j.jaip.2021.04.018. Epub 2021 Apr 22.
Coronavirus disease 2019 (COVID-19) necessitated wide-scale adoption of telemedicine (TM) and restriction of in-person care. The impacts on allergy/immunology (A/I) care delivery are still being studied.
To describe the outcomes of rapid transition to TM-based care (video visit followed by in-person visits dedicated to diagnostic and therapeutic procedures when needed) at an academic A/I practice during COVID-19.
Demographic data were compared for patients originally scheduled for in-person visits between March 10, 2020, and April 30, 2020, who completed a video visit instead between March 10, 2020, and June 30, 2020, and those who did not. Appointment completion, diagnoses, and drug allergy and skin testing completion were compared for visits between March 10, 2020, and June 30, 2020, and 1 year prior (March 10, 2019-June 30, 2019).
Sixty-nine percent (265 of 382) of patients originally scheduled between March 10, 2020, and April 30, 2020, were able to complete video visits. Patients who completed video visits were more likely to be white (52% vs 33%; P < .001), English-speaking (96% vs 89%; P = .01), and privately insured (70% vs 54%; P = .004). With TM-based care compared with in-person care, there were significant decreases in environmental and food skin testing completion rates (91% and 92% in 2019 vs 60% and 64% in 2020, respectively, P < .001). Drug allergy testing completed after internal referral remained low but comparable (51% in 2019 vs 52% in 2020). Transitioning nonprocedural visits to video allowed allergen immunotherapy and biologic injection visits to resume at a volume similar to pre-COVID. No COVID-19 infections resulted from in-clinic exposure.
Although transitioning to TM-based care allowed continued A/I care delivery, strategies are needed to achieve higher testing completion rates and ensure video visits do not exacerbate existing health disparities.
2019 年冠状病毒病(COVID-19)需要广泛采用远程医疗(TM)并限制亲自就诊。其对过敏/免疫学(A/I)护理的影响仍在研究中。
描述在 COVID-19 期间,一家学术性 A/I 实践快速过渡到基于 TM 的护理(视频就诊,随后在需要时进行专门的诊断和治疗程序)的结果。
比较 2020 年 3 月 10 日至 4 月 30 日期间最初安排亲自就诊的患者的人口统计学数据,这些患者在 2020 年 3 月 10 日至 6 月 30 日期间完成了视频就诊,而未完成视频就诊的患者。比较 2020 年 3 月 10 日至 6 月 30 日和 1 年前(2019 年 3 月 10 日至 6 月 30 日)就诊的患者的预约完成情况、诊断以及药物过敏和皮肤测试完成情况。
69%(265/382)最初安排在 2020 年 3 月 10 日至 4 月 30 日期间就诊的患者能够完成视频就诊。完成视频就诊的患者更可能是白人(52%比 33%;P<0.001)、说英语(96%比 89%;P=0.01)和私人保险(70%比 54%;P=0.004)。与亲自就诊相比,基于 TM 的护理显著降低了环境和食物皮肤测试的完成率(2019 年分别为 91%和 92%,2020 年分别为 60%和 64%,P<0.001)。内部转诊后完成的药物过敏测试仍然较低,但保持不变(2019 年为 51%,2020 年为 52%)。将非程序就诊转换为视频就诊使变应原免疫治疗和生物制剂注射就诊能够以类似于 COVID 之前的水平恢复。在临床暴露中没有 COVID-19 感染的发生。
尽管过渡到基于 TM 的护理允许继续提供 A/I 护理,但需要采取策略来提高测试完成率,并确保视频就诊不会加剧现有的健康差异。